Tomita Y, Katsura T, Okano T, Inui K, Hori R
Department of Pharmacy, Kyoto University Hospital, Faculty of Medicine, Kyoto University, Japan.
J Pharmacol Exp Ther. 1990 Feb;252(2):859-62.
Bestatin [(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl-L-leucine], a potent inhibitor of aminopeptidase B and leucine aminopeptidase, enhances the immune response to activate the defense mechanism of the living organism and suppresses the growth and metastasis of cancer. Bestatin has been effectively used by p.o. administration, but the mechanisms of intestinal absorption remain to be solved. The present study was undertaken to examine whether bestatin, a dipeptide containing an unusual amino acid, is transported via dipeptide carriers in intestinal brush-border membranes, by using cephradine as a probe for the H+/dipeptide cotransport system. The initial uptake of cephradine in the presence or absence of an inward H+ gradient, driving force, was inhibited by bestatin and this inhibition occurred in a competitive manner (Ki = 0.47 mM). The uptake of cephradine was stimulated by the countertransport effect of bestatin, the definitive criterion for ascertaining a common transport system. These findings indicate that bestatin, as well as cephradine and other p.o. cephalosporins, can be transported via dipeptide carriers in intestinal brush-border membranes.
贝司他汀[(2S,3R)-3-氨基-2-羟基-4-苯基丁酰-L-亮氨酸]是氨肽酶B和亮氨酸氨肽酶的强效抑制剂,可增强免疫反应以激活生物体的防御机制,并抑制癌症的生长和转移。贝司他汀已通过口服给药有效应用,但其肠道吸收机制仍有待解决。本研究旨在通过使用头孢拉定作为H⁺/二肽共转运系统的探针,研究含有不寻常氨基酸的二肽贝司他汀是否通过肠刷状缘膜中的二肽载体转运。在存在或不存在内向H⁺梯度(驱动力)的情况下,头孢拉定的初始摄取受到贝司他汀的抑制,并且这种抑制以竞争性方式发生(Ki = 0.47 mM)。贝司他汀的逆向转运效应刺激了头孢拉定的摄取,这是确定共同转运系统的决定性标准。这些发现表明,贝司他汀以及头孢拉定和其他口服头孢菌素可以通过肠刷状缘膜中的二肽载体转运。